The role of XXXX gene polymorphisms in determining the susceptibility and prognosis of @entity1149 in Chinese @entity1 .

@entity1 @entity13156 @entity5 @entity13159 @entity2 @entity1149 @entity13161 @entity534 @entity7647 @entity13157 @entity204
AIM: Although the role of genetic polymorphisms of @entity13156 ( @entity13156 ) gene in several @entity5 has been documented, the association between polymorphisms of @entity13156 gene and @entity2 remains unknown. METHOD: We recruited 744 @entity1 histologically diagnosed as @entity1149 ( @entity1149 ) and 832 controls in this study. Polymorphism analysis of @entity13156 gene was performed by PCR-restriction fragment length polymorphisms. RESULTS: The @entity534 / @entity534 genotype and @entity534 allele frequency of the @entity13159 in @entity13156 gene were significantly prevalent in @entity1149 subjects than in controls (P  <  0.05). The odd ratio (OR) for @entity1149 in @entity534 / @entity534 genotype carriers was 3.12 (95% CI: 2.25-4.56, P  =  0.0023, with @entity7647 / @entity7647 as reference). There were no significant differences in the genotype distributions and allele frequencies of @entity13157 and @entity13161 in @entity13156 gene between @entity1149 cases and controls (All P  >  0.05). The @entity534 / @entity534 carriers had higher @entity5 grade and higher TNM stage. Kaplan-Mier curve showed the @entity534 / @entity534 carriers had a poor prognosis than those with @entity7647 / @entity534 and @entity7647 / @entity7647 genotype carriers. Cox proportional hazards regression models showed the hazard ratio (HR) for @entity204 associated with @entity534 / @entity534 genotype was 3.43 (95% CI: 2.45-5.92, compared with @entity7647 / @entity7647 carriers, P  =  0.002). The other two SNPs of @entity13156 gene did not show this trend in the evaluation of their role in determining the prognosis of @entity1149 subjects. CONCLUSION: The results suggest the polymorphisms of @entity13159 , rather than @entity13157 and @entity13161 , may be used as a molecular marker for progression and prognosis of @entity1149 .
